Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AMRX 
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2025: AMRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 1 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.68% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/18/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.02B USD | Price to earnings Ratio 961 | 1Y Target Price 12.5 |
Price to earnings Ratio 961 | 1Y Target Price 12.5 | ||
Volume (30-day avg) 4 | Beta 1.19 | 52 Weeks Range 6.68 - 10.34 | Updated Date 09/17/2025 |
52 Weeks Range 6.68 - 10.34 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.12% | Operating Margin (TTM) 15.46% |
Management Effectiveness
Return on Assets (TTM) 6.85% | Return on Equity (TTM) -881.26% |
Valuation
Trailing PE 961 | Forward PE 6.3 | Enterprise Value 5569481469 | Price to Sales(TTM) 1.06 |
Enterprise Value 5569481469 | Price to Sales(TTM) 1.06 | ||
Enterprise Value to Revenue 1.95 | Enterprise Value to EBITDA 9.54 | Shares Outstanding 314079309 | Shares Floating 168757954 |
Shares Outstanding 314079309 | Shares Floating 168757954 | ||
Percent Insiders 46.48 | Percent Institutions 45.93 |
Upturn AI SWOT
Amneal Pharmaceuticals, Inc. Class A Common Stock
Company Overview
History and Background
Amneal Pharmaceuticals was founded in 2002. It is a generics and specialty pharmaceutical company focused on developing, manufacturing, and distributing a broad range of pharmaceutical products. They have grown through organic development and strategic acquisitions.
Core Business Areas
- Generics: Develops, manufactures, and markets a wide range of generic pharmaceutical products across various therapeutic areas.
- Specialty: Focuses on developing and commercializing differentiated branded products, including complex generics and biosimilars.
Leadership and Structure
Niraj Patel and Chirag Patel serve as Co-Chief Executive Officers. The company has a standard corporate structure with functional departments like R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Generic Pharmaceuticals: A broad portfolio of generic drugs across various therapeutic areas. Market share varies by product. Competition includes Teva Pharmaceuticals (TEVA), Mylan (VTRS), and Sandoz (RDHL).
- Specialty Products: Includes proprietary formulations and complex generics. The exact market share is product-dependent. Competitors depend on the product line.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, regulatory scrutiny, and increasing pricing pressure. The generic segment is particularly competitive, while specialty pharmaceuticals offer higher margins but also greater risk.
Positioning
Amneal positions itself as a vertically integrated generic and specialty pharmaceutical company with a focus on cost-effective manufacturing and strategic product development.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be over $1 trillion. Amneal targets segments within this market, focusing on generics and specialty products. Their TAM is in the billions, depending on specific product focus.
Upturn SWOT Analysis
Strengths
- Vertically integrated manufacturing
- Diverse product portfolio
- Established distribution network
- Strong R&D capabilities
- Experienced management team
Weaknesses
- High debt levels
- Exposure to pricing pressure in generics market
- Dependence on successful product launches
- Regulatory compliance risks
Opportunities
- Biosimilar development
- Expansion into emerging markets
- Strategic acquisitions
- New product launches
- Partnerships and collaborations
Threats
- Increased competition
- Regulatory changes
- Patent expirations
- Pricing pressure
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- RDHL
- Endo International plc (ENDPQ)
- Lupin Limited (LUPIN.NS)
Competitive Landscape
Amneal faces intense competition from established generic and specialty pharmaceutical companies. Its competitive advantage lies in its vertical integration and cost structure. Disadvantages include high debt and pricing pressure.
Major Acquisitions
Actavis plc's ANDA Business
- Year: 2017
- Acquisition Price (USD millions): 3200
- Strategic Rationale: Expanded product portfolio and manufacturing capabilities in generic pharmaceuticals.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by product launches, acquisitions, and market expansion. The growth rate varies depending on the period.
Future Projections: Analyst estimates are readily available from financial news sources and research reports. Future growth relies on pipeline execution and market dynamics.
Recent Initiatives: Recent initiatives include new product launches, strategic partnerships, and cost optimization programs.
Summary
Amneal Pharmaceuticals has a diversified portfolio and vertically integrated manufacturing, which are strengths. Its high debt and exposure to pricing pressures create challenges. Successful product launches and market expansion are crucial for future growth, while regulatory changes and competition pose threats. The company must focus on reducing debt and innovating within its specialty segment to thrive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Amneal Pharmaceuticals Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Exchange NYSE | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2009-01-15 | Co-Founder, Co-CEO, President & Director Mr. Chirag K. Patel | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8300 | Website https://www.amneal.com |
Full time employees 8300 | Website https://www.amneal.com | ||
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.